ClinVar Miner

Submissions for variant NM_000059.3(BRCA2):c.3229_3231GTT[1] (p.Val1078del) (rs1064795381)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 2
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Color RCV000580575 SCV000683537 uncertain significance Hereditary cancer-predisposing syndrome 2018-04-24 criteria provided, single submitter clinical testing
GeneDx RCV000479531 SCV000571132 uncertain significance not provided 2016-07-28 criteria provided, single submitter clinical testing This in-frame deletion of 3 nucleotides in BRCA2 is denoted c.3232_3234delGTT at the cDNA level and p.Val1078del (V1078del) at the protein level. The normal sequence, with the bases that are deleted in braces, is AGTT[GTT]TCTG. This deletion of a single Valine residue occurs at a position where amino acids with properties similar to Valine are tolerated across species and is located in the RAD51 binding domain (Roy 2012). This variant has not, to our knowledge, been published in the literature as pathogenic or benign. Since in-frame deletions may or may not inhibit proper protein functioning, the clinical significance of this finding remains unclear at this time and we consider BRCA2 Val1078del to be a variant of uncertain significance.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.